All News
Kharouf et al. Effect of handedness on radiographic damage in PsA. Left-handedness associated increased peripheral damage, especially in left hand. Hypothesis that having to use tools designed for right-handedness increases mechanical stress @RheumNow #ACR25 Abstr#1415 https://t.co/gfGQkrYyc8
Richard Conway RichardPAConway ( View Tweet)
Bimekizumab showed sustained 1-year efficacy in axSpA across age, BMI, CRP, and HLA-B27 subgroups. ASAS40, ASDAS, BASDAI, ASQoL, and MRI scores improved in most groups—especially age ≤35, BMI 25–30, CRP >5, and HLA-B27+. Abstract 1451 @RheumNow #ACR25
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Simko et al. 6-monthly vs 3-monthly MTX lab monitoring. 3821 patients. Appears to be no difference. Potential for significant cost-savings and reduced burden to patients. @RheumNow #ACR25 Abstr#1370 #ACRbest https://t.co/G3tNQq8qXT
Richard Conway RichardPAConway ( View Tweet)
Post-hoc analysis of CARE(Ph2B) Study to assess sustained responses in mSLEDAI-2K vs. PBO x 12mos in pts given Cenerimod
Sustained response in Cenerimod Ex-4mg (63.5%) > PBO (50%); HR 1.43
Ongoing research, further data needed.
#ACR25 @RheumNow Abs1519 https://t.co/cQbVVIIyxW
sheila RHEUMarampa ( View Tweet)
Really useful observational study, 305 pts with TAK
Out of 205 pts w/subsequent imaging, 72 (35%) w/NEW lesions in previously-unaffected territory
Majority of lesions stenotic. Emphasizes importance of regular monitoring
#ACR25 @RheumNow Abstr#1631 https://t.co/zoWjH0lEym
Links:
Mike Putman EBRheum ( View Tweet)
Prednisone remains both lifeline and liability.
New PRED-SAFE SDM tool helps patients and clinicians navigate that tension—visualizing benefits and harms to guide tapering. In pilot testing, 93% had no residual decisional conflict.
@RheumNow #ACR25 Abstract#1052 #ACRbest https://t.co/CgQ75N7A1p
Jiha Lee JihaRheum ( View Tweet)
Picture this 👉radiographic joint damage tied to worse physical function in #PsA:
🔹 ↑ mSS → ↑ HAQ (β=0.003 [0.002–0.004])
🔹 ↑ mSS → ↓ SF-36 PF (β=−0.10 [−0.15 to −0.05])
🔹 ↑ # of damaged joints → worse physical function
@RheumNow #ACR25 Abstract 1425
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Abstract 0878: In PsA pts w/ lateral epicondyle enthesitis on secukinumab (n=11):
🔹 Improved DAPSA & SPARCC scores
🔹 entheseal tissue biopsy showing shift toward pro-resolving fibroblasts (↑DKK3/CD200⁺)
🔹 ↓ osteoblast-related pathways
@RheumNow #ACR25
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Mayer et al. NSAIDs in IBD. Retrospective cohort study. 250000 individuals. Non-inferiority study. No increased IBD-related hospitalisation in UC, but an increase in all-cause hospitalisation. @RheumNow #ACR25 Abstr#1434 https://t.co/he2Xmcqslk
Richard Conway RichardPAConway ( View Tweet)
A combined biomarker assay may predict which AAV patients will not respond to RTX therapy
A next step towards precision / personalized rheumatology?
@RheumNow #ACR25 Abst 1602 https://t.co/gcrZUNV0b9
Links:
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
#1263 More from our health literacy work!
@KingsCollegeNHS, 11 distinct health literacy profiles were identified from 263 rheum patients. Lower literacy linked to unemployment & non-White ethnicity, highlighting equity gaps in care & need for improved resources
@RheumNow #ACR25 https://t.co/QxzMFLykyE
Mrinalini Dey DrMiniDey ( View Tweet)
#1639
In 2 lupus cohorts (n=619), 1 in 4 had mismatch between self-reported & measured physical function.
Higher BMI, disease activity & depression linked to underreporting ability ➡️ self-report ≠ performance! Important for SLE care & research. @RheumNow #ACR25 https://t.co/kMlChreJPh
Mrinalini Dey DrMiniDey ( View Tweet)
GLP1 receptors are present on cartilage, synovial and specific cells such as macrophages.
Also endogenous GLP1 seemed to protect the cartilage in animal models
#ACR25 @RheumNow https://t.co/ekNWbtPO4b
Links:
Bella Mehta bella_mehta ( View Tweet)
The axSpA Registry of Ireland (ASRI): 10% reported depression, w/ higher prev in older cohorts.
Pts w/ depression had ⬆️peripheral involvement, ⬆️dse activity & poor functional status
💡Consider the impact of non-inflamm factors in dse burden
#ACR25 @RheumNow Abs1409 https://t.co/yDfHA24M6e
sheila RHEUMarampa ( View Tweet)
NEREA registry study on mortality in progressive pulmonary fibrosis in SARD-ILD. 158 patients. Median survival 7.8 years. DMARD use associated improved mortality. @RheumNow #ACR25 Abstr#1024 https://t.co/rK1caGi2r4
Richard Conway RichardPAConway ( View Tweet)
POETYK-PsA 1 & 2 Phase 3 RCT TYK2i Deucravacitinib
Pooled analysis 640+pts PBO vs. 640+pts DEUCRA 6mg QD
MDA 12% vs 22%
All elements of MDA response sig different except for Leeds enthesitis index
DAPSA Remission 2% vs. 9%
PsARC 42% vs. 61%
PASDAS -1 vs. -1.7
mCPDAI -1.2 vs. -1.9 https://t.co/OTOFxTOrRp
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
GLP-1 receptor agonists reduce mortality in PsA
Tsibadze et al retrospectively compared ~4k PsA on GLP-1 to ~86k PsA not
After propensity matching, those treated with GLP-1:
- lower risk MACE
- lower risk overall death
@RheumNow #ACR25 Abst 0849 https://t.co/EuojrDq0Fj
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Abstract 0874:
At wk16, deucravacitinib (vs placebo) showed greater efficacy in multiple #PsA disease activity measures
🔹 ↑ MDA, DAPSA LDA/remission, and PsARC responses
🔹 Greater ↓in PASDAS and mCPDAI
🔹 Benefits seen in both men and women
@RheumNow #ACR25
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Open-label MTX vs. Toci in GCA in METOGiA
Wk 78:
37% w/o relapse in MTX arm
46% w/o relapse in Toci arm
MTX was NOT non-inferior to Toci
Toci superior in 2ndary endpoints
Cumulative doses GC not significantly different
#ACR25 #ACRBest @RheumNow Abst 0891 https://t.co/lCaP4EdJ9C
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
HOPE for Pts w #fibromyalgia #FM
#Transcutaneous #electrical #nerve #stimulation + #physio
Is
Better than #PT alone
#Pragmatic #cluster #randomized #trial
Answered impt question
Does #TENS help Pts w #fibro
Too ba noTENS sham
Abst#LB03 #ACR25 #ACRBest @RheumNow @ACRheum https://t.co/fGyAugFtcN
Janet Pope Janetbirdope ( View Tweet)
